Danaher Co. (NYSE:DHR) Shares Sold by Bancreek Capital Management LP

Bancreek Capital Management LP decreased its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 46.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,589 shares of the conglomerate's stock after selling 28,424 shares during the quarter. Danaher makes up approximately 7.3% of Bancreek Capital Management LP's portfolio, making the stock its 4th biggest position. Bancreek Capital Management LP's holdings in Danaher were worth $7,481,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Howard Capital Management Group LLC boosted its holdings in shares of Danaher by 4.1% in the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate's stock valued at $342,000 after buying an additional 48 shares in the last quarter. Citizens Financial Group Inc. RI lifted its position in Danaher by 17.3% in the third quarter. Citizens Financial Group Inc. RI now owns 16,940 shares of the conglomerate's stock valued at $4,713,000 after acquiring an additional 2,499 shares during the last quarter. LPL Financial LLC boosted its stake in Danaher by 7.4% in the third quarter. LPL Financial LLC now owns 379,341 shares of the conglomerate's stock valued at $105,464,000 after acquiring an additional 26,124 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Danaher by 0.4% during the third quarter. Pacer Advisors Inc. now owns 51,110 shares of the conglomerate's stock worth $14,210,000 after purchasing an additional 220 shares in the last quarter. Finally, Lathrop Investment Management Corp lifted its holdings in shares of Danaher by 13.8% in the 3rd quarter. Lathrop Investment Management Corp now owns 25,705 shares of the conglomerate's stock valued at $7,147,000 after purchasing an additional 3,125 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Danaher Price Performance

Danaher stock traded down $2.25 during midday trading on Wednesday, reaching $210.15. The company's stock had a trading volume of 2,669,221 shares, compared to its average volume of 3,011,853. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The firm has a market capitalization of $150.19 billion, a PE ratio of 39.80, a P/E/G ratio of 2.66 and a beta of 0.82. The stock's 50 day simple moving average is $216.41 and its 200 day simple moving average is $237.75.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the business earned $2.09 earnings per share. On average, equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This is a boost from Danaher's previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a yield of 0.61%. Danaher's payout ratio is currently 24.24%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on DHR shares. Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 price target on the stock in a research report on Friday, March 14th. Bank of America raised shares of Danaher from a "neutral" rating to a "buy" rating and set a $290.00 target price on the stock in a report on Friday, December 13th. Wells Fargo & Company decreased their price target on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a research note on Thursday, January 30th. Citigroup dropped their price objective on shares of Danaher from $285.00 to $265.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, Robert W. Baird lowered their price target on Danaher from $277.00 to $268.00 and set an "overweight" rating on the stock in a report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $278.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.